What Drotaverine Treats: Main Uses and Benefits

Drotaverine is generally used to provide supportive relief from pain and cramping caused by involuntary contractions (spasms) in certain internal organ systems. This medication is indicated for symptoms associated with conditions such as colic, spasms related to the urinary tract (like those from kidney stones), and menstrual cramps.

It is applied across domains where additional symptomatic support is needed, often during phases when symptoms become more noticeable.

“The medication is applied across domains where additional symptomatic support is needed.”

Symptom and Therapeutic Support

Drotaverine helps address symptom clusters that may become intense or disruptive, focusing on symptoms related to physical discomfort and internal pressure. It is commonly used when symptom clusters, such as severe discomfort or colic, interfere with daily functioning. The main therapeutic benefit is that it contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes.

• Quick Fact: Relief for Spasm-Related Pain

Who can and cannot use Drotaverine? — Official Regulatory Information

Drotaverine is a medication with specific eligibility criteria defined by regulatory documents, primarily focusing on conditions and patient populations where use is considered contraindicated or not recommended.

Use requires special caution in all patients with hypotension (low blood pressure) due to the risk of further decrease. Individuals with rare hereditary problems, such as galactose intolerance or glucose-galactose malabsorption, should not use this medicine due to the presence of excipient lactose.

Interactions with Other Medicines and Products

The interaction profile of Drotaverine is defined by documented pharmacodynamic and exposure-modifying effects, as stated in regulatory prescribing information. The substance primarily demonstrates pharmacodynamic (PD) interactions leading to either potentiation or antagonism of co-administered medicines.

Documented Interaction Patterns

Population-Specific Interaction Restriction

Co-administration with Levodopa is not recommended in patients with Parkinson's Disease due to the officially documented antagonistic effect that results in decreased efficacy of the antiparkinsonian medication. No mandatory timing or dose separation requirements between Drotaverine and other medicines are documented in official regulatory labels. The official interaction profile does not include warnings for interactions with food or alcohol.

Drotaverine is a musculotropic agent that exerts a direct action on smooth muscle cells, operating independently of the autonomic nervous system. Its mechanism is rooted in selective competitive inhibition of the enzyme Phosphodiesterase 4 ( PDE4).

Enzyme Inhibition and the cAMP Relaxation Cascade

By blocking PDE4, Drotaverine prevents the hydrolysis of cyclic adenosine monophosphate ( cAMP), causing a sharp increase in intracellular cAMP concentration. This elevated cAMP activates Protein Kinase A ( PKA), which is a necessary step in the downstream cascade that modulates smooth muscle tone.

Inactivation of the Contraction Mechanism

The PKA-driven cascade proceeds to phosphorylate and deactivate Myosin Light-Chain Kinase ( MLCK). Since MLCK is required for the phosphorylation of the myosin light chain, its suppression prevents the formation of the actin-myosin cross-bridge—the fundamental molecular event of contraction. The resulting physiological consequence of this molecular interference is direct relaxation of smooth muscle tissue (spasmolysis), leading to a reduction of muscle hypertonicity.

Drotaverine hydrochloride is officially administered via two primary routes: the oral route, typically provided as 40 mg or 80 mg tablets, and the parenteral route, delivered as an injection solution, generally given intramuscularly (IM) or intravenously (IV) in a supervised clinical setting.

For oral use in adults, the standardized total daily dose ranges from 120 mg to 240 mg, with the maximum recommended daily limit being 240 mg. This total amount is specified to be taken in 2 to 3 separate, divided doses over the course of the day. Tablets are generally instructed to be administered with a full glass of water.

Specific dosing constraints exist for pediatric patients. Children between 6 and 12 years have a maximum daily dose of 80 mg, separated into two daily administrations. For adolescents above 12 years, the maximum daily allowance is 160 mg, which may be partitioned into two to four doses. Dosing for the injectable form is typically 40 mg to 80 mg per administration, given up to three times daily.

The use of Drotaverine is intended for short-term symptomatic management. In the event of a missed dose, the procedural instruction is to not take a double dose to compensate, but rather to resume the regular dosing schedule at the next designated time. Medical supervision is required when administering the drug to patients with known hepatic or renal impairment.

Research evidence / Overview of studies for Drotaverine

Evidence for Spasms Associated with Irritable Bowel Syndrome (IBS)

Research has explored how symptoms change during the observation of Drotaverine administration in adults experiencing abdominal pain and cramping as part of Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating or episodic manifestations. Studies conducted during periods of increased symptom activity have primarily included short-term randomized controlled trials (RCTs) and systematic reviews. These trials were designed to examine outcomes related to physical discomfort, mainly focusing on symptom intensity or variability.

Findings from this research describe patterns observed in the studies regarding the measurement of abdominal pain scores compared to a control group (often placebo). Studies report how symptoms evolved in the observed populations over defined, typically short time intervals of a few weeks. Long-term effects are not fully established for this indication, as follow-up durations were limited in many key trials.

Research on Acute Pain from Renal Colic (Kidney Stones)

Drotaverine was studied for its role during acute or disruptive episodes of pain, specifically acute renal colic, which is characterized by painful spasms related to kidney or ureteric stones. Research on this condition utilizes RCTs conducted in settings with varying symptom burdens. Studies focused on outcomes describing episodic or acute changes, such as the time required to record a change in pain intensity and the need for additional rescue pain medication.

Acute care studies reported findings describing patterns observed in the studies regarding the measurement of changes in pain intensity following administration. Findings describe patterns related to the time intervals measured during the study period. The research primarily explores short-term symptom changes, meaning the follow-up durations were limited to the immediate period of pain management. Limited information for long-term outcomes exists, as the studies did not track the effect on the passage of the stone itself.

Evaluating Evidence in Special Populations

Beyond the general adult population, research has examined the use of Drotaverine for recurrent abdominal pain in children. These pediatric studies utilized randomized, placebo-controlled designs to observe responses over defined time intervals. Outcomes included patient-reported outcomes describing perceived discomfort, along with parent-reported measures of activity level.

Evidence quality varies across studies for this group, and the sample sizes were modest in key pediatric trials. Data are still emerging regarding the overall evidence landscape in this population, and there is a documented need for larger, more consistent trials in children to improve the certainty of the findings.

Key Studies & References

1. Efficacy and safety of combination therapy with drotaverine and ketorolac versus ketorolac monotherapy for acute renal colic: a retrospective study of 322 patients - Semantic Scholar
2. Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial - Semantic Scholar
3. Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners—An Observational, Retrospective, Cross-Sectional Study Using Real-World Data - MDPI

Common questions about Drotaverine (FAQ)

Q: What is Drotaverine used for?

A: Drotaverine is a medication that belongs to a class of drugs called antispasmodics. It is used to help alleviate spasms of the smooth muscles associated with certain conditions. It may be prescribed for conditions such as pain related to smooth muscle spasms of the biliary tract, urinary tract, or gastrointestinal tract, based on a clinician's assessment.

Q: How does Drotaverine work?

A: Drotaverine works by inhibiting the enzyme phosphodiesterase type 4 ( PDE4) within the smooth muscle cells. This inhibition can lead to an increase in intracellular cAMP, which ultimately results in the relaxation of the smooth muscles. This action is thought to be the basis for its anti-spasmodic effects.

Q: Is Drotaverine suitable for use during pregnancy?

A: The use of Drotaverine during pregnancy should be discussed with a healthcare provider. Limited data are available regarding its safety in pregnant individuals. A healthcare professional is best suited to weigh the potential benefits against any possible risks in this specific context.

Q: Can Drotaverine cause drowsiness?

A: Like many medications, Drotaverine may be associated with side effects, including dizziness or headache. Although not a universal experience, these effects could impact the ability to drive or operate machinery. Patients should observe how they react to the medication before engaging in activities that require alertness.

How to Store and Dispose of Drotaverine?

Regulatory documents specify strict conditions for storing Drotaverine hydrochloride to ensure product stability.

Official Storage Requirements

• Temperature: The product must be stored at a temperature not exceeding 30 C.
• Packaging: Storage must occur in the original package.
• Protection: The medicine must be protected from light and moisture.
• Child Safety: It is mandatory to store the medicine out of the sight and reach of children.

Disposal Instructions

Regulatory labeling states that there are No Special Requirements for the disposal of the unused product. This classification indicates that the medicine is not considered hazardous waste; however, disposal must still comply with standard local procedures for discarding unused or expired medicinal products.